文献速递心脑血管急症消化、代谢与肾脏急症

强化与标准降糖治疗对急性缺血性卒中患者功能结局的影响:SHINE随机临床试验

Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01
一句话结论急性缺血性卒中伴高血糖患者,强化静脉胰岛素降糖(目标80-130 mg/dL)与标准皮下胰岛素治疗相比,90天良好功能结局无显著差异,且强化组严重低血糖更多,作者认为不支持在此情况下使用强化降糖。

SHINE随机临床试验纳入1151例急性缺血性卒中伴高血糖的成人患者(糖尿病者血糖>110 mg/dL,非糖尿病者≥150 mg/dL),发病12小时内入组,来自美国63个中心。患者随机接受计算机决策支持的持续静脉胰岛素强化治疗(目标80-130 mg/dL,n=581)或皮下滑动刻度胰岛素标准治疗(目标80-179 mg/dL,n=570),最长72小时。主要终点90天改良Rankin量表良好结局在强化组为20.5%(119/581),标准组为21.6%(123/570),校正相对风险0.97(95%CI 0.87-1.08,P=0.55),无显著差异。强化组因低血糖或其他不良事件提前终止治疗者11.2%(65/581),标准组3.2%(18/570);严重低血糖仅见于强化组(15/581,2.6%)。作者结论认为这些发现不支持在此情况下使用强化血糖控制。

要点

  • 急性缺血性卒中伴高血糖患者,强化静脉胰岛素降糖(目标80-130 mg/dL)与标准皮下胰岛素治疗(目标80-179 mg/dL)相比,90天良好功能结局无显著差异(20.5% vs 21.6%,校正RR 0.97,95%CI 0.87-1.08,P=0.55)。
  • 强化组因低血糖或其他不良事件提前终止治疗的比例为11.2%(65/581),标准组为3.2%(18/570)。
  • 严重低血糖仅发生于强化组,为2.6%(15/581),风险差2.58%(95%CI 1.29%-3.87%)。
  • 研究因预设中期分析显示无效而提前终止入组。
  • 作者结论认为,这些发现不支持在急性缺血性卒中伴高血糖时使用强化血糖控制。

适用人群与场景

  • 成人急性缺血性卒中伴高血糖患者:有糖尿病者血糖>110 mg/dL,无糖尿病者血糖≥150 mg/dL,发病12小时内入组,来自美国63个中心。

处置流程与药物剂量

  • 强化治疗组:使用计算机决策支持工具进行持续静脉胰岛素输注,目标血糖浓度80-130 mg/dL(4.4-7.2 mmol/L),最长72小时(n=581)。
  • 标准治疗组:皮下滑动刻度胰岛素,目标血糖浓度80-179 mg/dL(4.4-9.9 mmol/L),最长72小时(n=570)。

研究设计与关键结果

  • 研究类型:随机临床试验(SHINE),纳入1151例患者,来自美国63个中心,2012年4月至2018年8月入组,随访至2018年11月。
  • 人群特征:平均年龄66岁(SD 13.1),女性529例(46%),糖尿病920例(80%)。
  • 主要终点:90天改良Rankin量表良好结局,强化组119/581(20.5%)vs 标准组123/570(21.6%),校正相对风险0.97(95%CI 0.87-1.08,P=0.55);未校正风险差-0.83%(95%CI -5.72%至4.06%)。
  • 治疗期间平均血糖:强化组118 mg/dL(6.6 mmol/L),标准组179 mg/dL(9.9 mmol/L)。
  • 因低血糖或其他不良事件提前终止治疗:强化组65/581(11.2%),标准组18/570(3.2%)。
  • 严重低血糖:仅强化组发生15/581(2.6%),风险差2.58%(95%CI 1.29%-3.87%)。
  • 研究因预设中期分析显示无效而提前终止入组。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,这些发现不支持在急性缺血性卒中伴高血糖时使用强化血糖控制。
  • 强化组严重低血糖仅见于强化组(2.6%),且因低血糖或其他不良事件提前终止治疗的比例更高(11.2% vs 3.2%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Hyperglycemia during acute ischemic stroke is common and is associated with worse outcomes. The efficacy of intensive treatment of hyperglycemia in this setting remains unknown.

OBJECTIVES: To determine the efficacy of intensive treatment of hyperglycemia during acute ischemic stroke.

DESIGN, SETTING, AND PARTICIPANTS: The Stroke Hyperglycemia Insulin Network Effort (SHINE) randomized clinical trial included adult patients with hyperglycemia (glucose concentration of >110 mg/dL if had diabetes or ≥150 mg/dL if did not have diabetes) and acute ischemic stroke who were enrolled within 12 hours from stroke onset at 63 US sites between April 2012 and August 2018; follow-up ended in November 2018. The trial included 1151 patients who met eligibility criteria.

INTERVENTIONS: Patients were randomized to receive continuous intravenous insulin using a computerized decision support tool (target blood glucose concentration of 80-130 mg/dL [4.4-7.2 mmol/L]; intensive treatment group: n = 581) or insulin on a sliding scale that was administered subcutaneously (target blood glucose concentration of 80-179 mg/dL [4.4-9.9 mmol/L]; standard treatment group: n = 570) for up to 72 hours.

MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the proportion of patients with a favorable outcome based on the 90-day modified Rankin Scale score (a global stroke disability scale ranging from 0 [no symptoms or completely recovered] to 6 [death]) that was adjusted for baseline stroke severity.

RESULTS: Among 1151 patients who were randomized (mean age, 66 years [SD, 13.1 years]; 529 [46%] women, 920 [80%] with diabetes), 1118 (97%) completed the trial. Enrollment was stopped for futility based on prespecified interim analysis criteria. During treatment, the mean blood glucose level was 118 mg/dL (6.6 mmol/L) in the intensive treatment group and 179 mg/dL (9.9 mmol/L) in the standard treatment group. A favorable outcome occurred in 119 of 581 patients (20.5%) in the intensive treatment group and in 123 of 570 patients (21.6%) in the standard treatment group (adjusted relative risk, 0.97 [95% CI, 0.87 to 1.08], P = .55; unadjusted risk difference, -0.83% [95% CI, -5.72% to 4.06%]). Treatment was stopped early for hypoglycemia or other adverse events in 65 of 581 patients (11.2%) in the intensive treatment group and in 18 of 570 patients (3.2%) in the standard treatment group. Severe hypoglycemia occurred only among patients in the intensive treatment group (15/581 [2.6%]; risk difference, 2.58% [95% CI, 1.29% to 3.87%]).

CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke and hyperglycemia, treatment with intensive vs standard glucose control for up to 72 hours did not result in a significant difference in favorable functional outcome at 90 days. These findings do not support using intensive glucose control in this setting.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01369069.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Johnston KC, Bruno A, Pauls Q, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019. PMID: 31334795. doi:10.1001/jama.2019.9346

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。